The National Cancer Institute (NCI) awarded Yale University a $499,238 federal grant (CFDA 93.395 - Cancer Treatment Research) to develop a novel tumor-targeted STING agonist (PHLIP-STINGA) that can enhance the effects of DNA-damaging cancer therapies in head and neck squamous cell carcinoma (HNSCC). The project aims to optimize the PHLIP-STINGA formulation to improve pharmacokinetics and tumor targeting, demonstrate synergy with DNA-damaging therapies in a STING-dependent manner, and identify the immunologic mechanisms underlying the enhanced tumor killing. The long-term goal is to translate these findings into a clinical trial testing PHLIP-STINGA in combination with DNA-damaging therapy for HNSCC patients. The project will be conducted at Yale University over a 5-year period from January 1, 2025 to December 31, 2029.
Generated 3/4/25, 8:38 AM